N

NovaBay Pharmaceuticals Inc
XBER:B9P

Watchlist Manager
NovaBay Pharmaceuticals Inc
XBER:B9P
Watchlist
Price: 0.114 EUR -11.63% Market Closed
Market Cap: €480.5k

Operating Margin

-69%
Current
Improving
by 6.7%
vs 3-y average of -75.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-69%
=
Operating Income
$-8.3m
/
Revenue
$14.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-69%
=
Operating Income
€-8.3m
/
Revenue
$14.2m

Peer Comparison

Country Company Market Cap Operating
Margin
US
NovaBay Pharmaceuticals Inc
XBER:B9P
480.5k EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
530.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP
Loading...
CH
Novartis AG
SIX:NOVN
222.3B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
267.6B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.1B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.2B EUR
Loading...

Market Distribution

Lower than 83% of companies in the United States of America
Percentile
17th
Based on 14 112 companies
17th percentile
-69%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

NovaBay Pharmaceuticals Inc
Glance View

Market Cap
480.5k EUR
Industry
Pharmaceuticals

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 29 full-time employees. The company went IPO on 2007-10-26. The firm develops and sells scientifically created and clinically proven eyecare and skincare products. Its product, Avenova Antimicrobial Lid & Lash Solution is used for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution. Its trademarks include Avenova, CelleRx, PhaseOne, NeutroPhase, DERMAdoctor, Kakadu C, AINT Misbehavin, KP Duty, and depictions of Dr. Audrey Kunin. Avenova Spray has broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. The Company, through its subsidiary DERMAdoctor, LLC, offers approximately 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration, and keratosis pilaris.

B9P Intrinsic Value
Not Available
N
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-69%
=
Operating Income
$-8.3m
/
Revenue
$14.2m
What is NovaBay Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for NovaBay Pharmaceuticals Inc is -69%, which is above its 3-year median of -75.7%.

How has Operating Margin changed over time?

Over the last 3 years, NovaBay Pharmaceuticals Inc’s Operating Margin has increased from -76.3% to -69%. During this period, it reached a low of -104.8% on Mar 31, 2023 and a high of -37.6% on Dec 31, 2023.

Back to Top